NCT02627287View on ClinicalTrials.gov

A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

PHASE1CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

February 25, 2016

Study Completion Date

February 25, 2016

Conditions
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DEVICE

FlexPen®

For subcutaneously (s.c. under the skin) injection.

DEVICE

DV3316 pen-injector

For subcutaneously (s.c. under the skin) injection.

DRUG

placebo

For subcutaneously (s.c. under the skin) injection

Trial Locations (2)

41460

Novo Nordisk Investigational Site, Neuss

55116

Novo Nordisk Investigational Site, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY